Humana Inc (NYSE:HUM) insider Roy A. Beveridge sold 4,622 shares of the firm’s stock in a transaction on Thursday, November 8th. The stock was sold at an average price of $341.06, for a total value of $1,576,379.32. Following the transaction, the insider now owns 10,621 shares in the company, valued at $3,622,398.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

HUM stock opened at $318.01 on Friday. The company has a current ratio of 1.68, a quick ratio of 1.68 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $45.83 billion, a price-to-earnings ratio of 23.93, a P/E/G ratio of 1.58 and a beta of 1.03. Humana Inc has a 1 year low of $231.90 and a 1 year high of $355.88.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, November 7th. The insurance provider reported $4.58 EPS for the quarter, beating analysts’ consensus estimates of $4.29 by $0.29. The company had revenue of $14.21 billion for the quarter, compared to analyst estimates of $13.97 billion. Humana had a return on equity of 19.10% and a net margin of 2.70%. During the same period last year, the company earned $3.39 earnings per share. As a group, analysts predict that Humana Inc will post 14.44 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 25th. Stockholders of record on Monday, December 31st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.63%. The ex-dividend date is Friday, December 28th. Humana’s dividend payout ratio (DPR) is 17.08%.

Several equities analysts recently issued reports on HUM shares. MED raised their target price on Humana from $350.00 to $373.00 and gave the company an “outperform” rating in a research note on Thursday, November 8th. Zacks Investment Research cut Humana from a “buy” rating to a “hold” rating in a research note on Friday, October 5th. Royal Bank of Canada raised their target price on Humana from $318.00 to $349.00 and gave the company a “sector perform” rating in a research note on Thursday, November 8th. Bank of America raised their target price on Humana from $338.00 to $375.00 and gave the company a “buy” rating in a research note on Thursday, August 2nd. Finally, Credit Suisse Group raised their target price on Humana from $370.00 to $390.00 and gave the company an “outperform” rating in a research note on Thursday, November 8th. Seven investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Humana has an average rating of “Buy” and an average price target of $352.30.

Several institutional investors and hedge funds have recently modified their holdings of HUM. Xact Kapitalforvaltning AB increased its holdings in shares of Humana by 2.7% during the second quarter. Xact Kapitalforvaltning AB now owns 26,255 shares of the insurance provider’s stock valued at $7,814,000 after purchasing an additional 694 shares during the period. Atria Investments LLC increased its holdings in shares of Humana by 18.4% during the second quarter. Atria Investments LLC now owns 6,588 shares of the insurance provider’s stock valued at $1,961,000 after purchasing an additional 1,024 shares during the period. Bank of Montreal Can increased its holdings in shares of Humana by 61.7% during the second quarter. Bank of Montreal Can now owns 413,429 shares of the insurance provider’s stock valued at $123,049,000 after purchasing an additional 157,752 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft MBH increased its holdings in shares of Humana by 987.3% during the second quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 10,873 shares of the insurance provider’s stock valued at $3,256,000 after purchasing an additional 9,873 shares during the period. Finally, Pendal Group Ltd increased its holdings in shares of Humana by 17.7% during the second quarter. Pendal Group Ltd now owns 100,549 shares of the insurance provider’s stock valued at $29,926,000 after purchasing an additional 15,125 shares during the period. 92.73% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Humana Inc (HUM) Insider Sells $1,576,379.32 in Stock” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2018/11/16/humana-inc-hum-insider-sells-1576379-32-in-stock.html.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Featured Article: Closed-End Mutual Funds (CEFs)

Insider Buying and Selling by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.